ASBP Aspire Biopharma Holdings, Inc.

Overview and Growth

In fiscal 2025, Aspire Biopharma Holdings, Inc. recorded $6.20K of revenue, net loss of $24.48M, and an operating cash outflow of $4.92M. Revenue of $6.20K sets the scale for evaluating how effectively sales translated into profit and cash during the year. Diluted earnings per share were -$16.38, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 1.49M, linking total earnings with the per-share result received by shareholders. The diluted share count was 116.7% higher than fiscal 2024, when diluted shares averaged 689.91K, adding context to the EPS comparison. Total assets stood at $1.31M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. The revenue-to-assets relationship was 0.0x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Direct costs exceeded revenue, producing a gross loss of $116.00 before operating expenses. The gross loss equaled 1.9% of revenue, quantifying the direct-cost deficit before operating expenses. Operations produced a $19.35M operating loss before non-operating and tax effects. The bottom-line result was a net loss of $24.48M after operating, financing, tax, and other recognized items. The company reported a pretax loss of $24.48M, before the effect of income taxes. The bottom-line deficit increased from $1.31M in fiscal 2024 to $24.48M.

Liquidity and Capital Structure

At period end, the $1.31M asset base was financed through $7.69M of liabilities and -$6.38M of equity. Equity was negative at -$6.38M, meaning liabilities exceeded the residual book value available to shareholders and weakening balance-sheet resilience. At period end, current assets of $1.31M compared with current liabilities of $7.59M, defining the company’s short-term resource position. Current assets covered only 0.17x of current liabilities, so current liabilities exceeded current assets at period end. Cash and equivalents totaled $1.00M, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 13.2% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Book equity represented -485.9% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 585.9% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 76.5% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 786.7% from $147.99K in fiscal 2024, leaving current total assets higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $4.92M, showing that operations absorbed cash during the period. Compared with a $265.19K operating cash outflow in fiscal 2024, the current outflow increased to $4.92M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.